Gunter von Minckwitz, MD, director of the German Breast Group Research Institute, discusses lessons learned from clinical trials examining neoadjuvant therapies in patients with breast cancer.

More research needs to be conducted to understand the optimal use of neoadjuvant therapy, von Minckwitz explains. Biomarkers have been developed in order to determine response to treatment, as well as serve as predictive markers of pathologic complete response rates and poor predictive markers of outcomes.

Additionally, researchers can develop findings from a correlative marker in the neoadjuvant setting that can be then confirmed to the adjuvant setting.

View more from the 33rd Annual Miami Breast Cancer Conference

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Breast Cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. von Minckwitz on Lessons Learned From Neoadjuvant Trials in Breast Cancer